 |
 |
 |
Pancreatic Diseases (PD) Educational Sessions |
|
| Educational Session #1 - Tuesday, February 1st, 2022 I 7PM Japan Time (GMT+9) | |
| 7:00-7:02 | Welcome & Introduction: Pancreatic Disorders - Pancreatic Exocrine Insufficiency |
| 7:02-7:14 | Prevalence and Diagnosis of Exocrine Pancreatic Insufficiency
David C. Whitcomb, MD, PhD |
| 7:14-7:29 | Gastroenterology follow up associated with Better Management of Exocrine Pancreatic Insufficiency Regardless of Etiology in Patients with Chronic Pancreatitis, Pancreatic Malignancy and Pancreatic Resection David C. Whitcomb, MD, PhD |
| 7:29-7:45 | Q&A: Panel discussion with faculty including questions sent from the audience |
| 7:45 | Closing |
| Educational Session #2 - Tuesday, February 8th, 2022, I 6PM CET | |
| 6:00-6:02 | Welcome & Introduction: Pancreatic Disorders - Pancreatic Cancer |
| 6:02-6:14 | Personalized Medicine in Pancreatic Cancer Elham Afghani, MD, MPH |
| 6:14-6:29 | Endoscopic Palliation of Pain in Pancreatic Cancer
Vikesh K. Singh, M.D., M.Sc. |
| 6:29-6:45 | Q&A: Panel discussion with faculty including questions sent from the audience |
| 6:45 | Closing |
| Educational Session #3 - Tuesday, February 15th, 2022, I 6PM Australia (AEDT)/New Zealand Time (GMT+11) | |
| 6:00-6:02 | Pancreatic Cystic Neoplasms and Fluid Collections |
| 6:02-6:14 | Personalized Medicine in Pancreatic Cance Santhi Swaroop Vege, MD, Master ACG, AGAF, FACP |
| 6:14-6:29 | Endoscopic Palliation of Pain in Pancreatic Cancer
Santhi Swaroop Vege, MD, Master ACG, AGAF, FACP |
| 6:29-6:45 | Q&A: Panel discussion with faculty including questions sent from the audience |
| 6:45 | Closing |
Inflammatory Bowel Disease (IBD) Educational Sessions |
|
| Educational Session #1 - Tuesday, February 15th, 2022 I 6PM CET | |
| 6:00-6:02 | Welcome & Introduction: Inflammatory Bowel Disease - A Review of Treatment Selection and Biologics |
| 6:02-6:14 | Positioning Therapies for UC Eugene F. Yen, MD |
| 6:14-6:29 | Choosing a Biologic in IBD
Eugene F. Yen, MD6:29-6:45 |
| Q&A: Panel discussion with faculty including questions sent from the audience | |
| 6:45 | Closing |
| Educational Session #2 - Tuesday, March 15th, 2022 I 6PM CET | |
| 6:00-6:02 | Welcome & Introduction: Inflammatory Bowel Disease - Outcomes of Adalimumab in Crohn's Disease |
| 6:02-6:14 | Adalimumab for Patients with Crohn's Disease Complicated By Intra-Abdominal Abscess: Long-Term Results of The Mica Study Raymond K. Cross, D, MS, AGAF, FACG |
| 6:14-6:29 | Adalimumab Is Associated with Decreased Healthcare Resource Utilization, Steroid Use and Disease Complications Compared to Vedolizumab as First-Line Biologic Therapy In Crohn’s Disease
Raymond K. Cross, D, MS, AGAF, FACG |
| 6:29-6:45 | Q&A: Panel discussion with faculty including questions sent from the audience |
| 6:45 | Closing |
| Educational Session #3 - Tuesday, April 19th, 2022 I 6PM CET | |
| 6:00-6:02 | Welcome & Introduction: Inflammatory Bowel Disease - Focus on Biosimilars |
| 6:02-6:14 | AGA Update: IBD and Biosimilars: What Health Care Providers Need to Know
Kian Keyashian, MD |
| 6:14-6:29 | New Agents For IBD: Biosimilars for all?
Kian Keyashian, MD |
| 6:29-6:45 | Q&A: Panel discussion with faculty including questions sent from the audience |
| 6:45 | Closing |